Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (11157)	8/3/2017 4:51:03 PM
From: tuck	Respond to of 12215

CARA: Whether or not CR845 works for pain, at least the company is executing in terms of staying on their deadlines. In today's earnings PR, they note the end of P2 with FDA for pruritus pivotal program (for I.V. formulation) will take place this quarter, with the P3 trial starting the next q. Last CC, they were fuzzier about that timing, saying by year end for the meeting. And if memory serves, they were guiding to 2018 for start of the trial. But then they got Breakthrough designation, and this is apparently a manifestation of it. Nor do I see slippage in the other programs. So, the stock is actually enjoying a slight after hours pop. Cheers, Tuck